×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Clinical: LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE
clinical
1,723 words
KG: LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD
Contents
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (46)
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.62
Pharmacological Enhancement of APOE4 Glycosylation
Score: 0.62
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.61
LRP1-Dependent Tau Uptake Disruption
Score: 0.60
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.54
Lysosomal Membrane Repair Enhancement
Score: 0.54
← Prev
pg 3/3
Related Analyses (22)
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Show 17 more
Related Experiments (13)
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease
validation · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40
ApoE4 Function in Alzheimer's Disease
validation · proposed · Score: 0.40
Biomarker-Guided Sequential Therapy Selection in Alzheimer's
clinical · proposed · Score: 0.40
Blood-Based Biomarker Panel for Early AD Detection
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Multi-omics analysis of myricanol effects on gene expression
exploratory · proposed · Score: 0.88
Anti-Tau Immunotherapy Dosing Optimization
clinical · proposed · Score: 0.40
Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo
clinical · proposed · Score: 0.40
Tau Propagation Causality Test — Does Tau Spread Drive Neuro
clinical · proposed · Score: 0.40
Show 8 more
See Also (15)
Neurodegeneration
disease · Pages share 12 hypotheses
APOE contributes to Alzheimer's disease by regulating b
hypothesis · Pages share 11 hypotheses
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 11 hypotheses
APOE4 (Apolipoprotein E4)
disease · Pages share 10 hypotheses
CALB1 (Calbindin 1)
gene · Pages share 10 hypotheses
APOE contributes to Alzheimer's disease by regulating b
hypothesis · Pages share 10 hypotheses
Microglia in Alzheimer's Disease Neurodegeneration
redirect · Pages share 10 hypotheses
Microglia in Alzheimer's Disease Neurodegeneration
cell · Pages share 10 hypotheses
LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy
clinical · Pages share 11 hypotheses
ALA-enriched Nutrition for APOE4 Carriers with MCI (NCT
clinical · Pages share 10 hypotheses
AAIC 2026: Cellular Pathophysiology and Neurodegenerati
event · Pages share 10 hypotheses
Extracellular Vesicle and Tunneling Nanotube-Mediated S
mechanism · Pages share 10 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
gene · Pages share 10 hypotheses
slc22a1
gene · Pages share 10 hypotheses
LRP1-Targeted ApoE-Mimetic Peptide Delivery
idea · Pages share 10 hypotheses
Show 10 more
Knowledge Graph (3 edges)
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD
references
LDLR
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD
references
LRP1
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD
references
APOE
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.